Plasmin activation system in restenosis: Role in pathogenesis and clinical prediction?

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 3, 1999, Pages 277-285

  Christ, Günter ^b   Kostner, Karam ^b   Zehetgruber, Manfred ^b   Binder, Bernd R ^b   Gulba, Dietrich ^b   Huber, Kurt ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Lipoprotein (a); Plasmin activation system; Plasminogen activator inhibitor type 1; Restenosis

Indexed keywords

LIPOPROTEIN A; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CELL PROLIFERATION; CORONARY ARTERY OBSTRUCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERPLASIA; LIPOPROTEIN(A); PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; RECURRENCE; TISSUE PLASMINOGEN ACTIVATOR; TUNICA INTIMA; URINARY PLASMINOGEN ACTIVATOR; WOUND HEALING;

EID: 0033063257     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008983110941     Document Type: Article

References (95)

1. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angioplasty follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-623.
2. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon. A quantitative angiographie study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77:361-371.
3. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-1687.
4. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86(Suppl 6): III47-III52.
5. Marmur JD, Poon M, Rossikhina M, Taubman MB. Induction of PDGP-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation 1992;86(Suppl. 6):III53-III60.
6. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28:1643-1651.
7. Bachmann F. The plasminogen-plasmin enzyme system. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott, 1994:1592-1622.
8. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-1072.
9. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-161.
10. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993;88:2030-2034.
11. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341: 1165-1168.
12. Wieczorek I, Ludlam CA, Fox KA. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am J Cardiol 1994;74:424-429.
13. Geppert A, Graft S, Beckman R, et al. Mass concentration of endogenous tPA in coronary artery disease: Relation to coronary risk factors, thrombotic events and aspirin treatment. Arterioscler Thromb Vase Biol 1998;18:1634-1642.
14. Speiser W, Speiser P, Minar E, et al. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localization of vessel disease and risk factors. Thromb Res 1990;59:77-88.
15. Geppert A, Beckmann R, Graf S, et al. Tissue-type plasminogen activator and type-1 plasminogen activator inhibitor in patients with coronary artery disease: Relation to clinical variables and cardiovascular risk factors. Fibrinolysis 1995;9(Suppl. I):109-113.
16. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996;78:405-414.
17. Okada SS, Grobmyer SR, Barnathan ES. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol 1996; 16:1269-1276.
18. 2-macroglobulin receptor associated protein. Thromb Haemost 1997;78:880-886.
19. Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of flbrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vase Biol 1996;16:539-545.
20. Shah PK, Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992;85:1279-1285.
21. Huber K, Jörg M, Probst P, et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992;67:209-213.
22. Brack MJ, More RS, Pringle S, Gershlick AH. Absence of a prothrombotic state in restenotic patients? Cor Art Dis 1994;5:501-506.
23. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty is a risk factor for restenosis. Circulation 1995;92:31-38.
24. Sakata K, Miura F, Sugino H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996;131:1-6.
25. Benchimol D, Bonnet J, Benchimol H, et al. Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty. Int J Cardiol 1993;38:7-18.
26. Kirschstein W, Simianer S, Dempfle CE, et al. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemost 1989;62:772-775.
27. Huber K, Beckmann R, Graf S, Geppert A, Probst P, Binder BR. Patients with recurrent restenosis after angioplasty exhibit a permanently decreased fibrinolytic potential. In: Gomez FP, Prentice C, Meyer J, eds, Coronary Thrombosis. New York: Raven Press, 1993:159-163.
28. Stegnar M, Mavri A. Reproducibility of flbrinolytic response to venous occlusion in healthy subjects. Thromb Haemost 1995;73:453-457.
29. Huber K, Kirchheimer JC, Ermler D, Bell C, Binder Br. Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: Characterization as tumor-associated antigen and comparison with alpha-fetoprotein. Cancer Res 1992;52:1717-1720.
30. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: Comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 1993;53:1788-1793.
31. Markus G. The relevance of plasminogen activators to neoplastic growth. A review of recent literature. Enzyme 1988;40:158-172.
32. Carroll V, Hattey E, Beckmann R, Griffiths MR, Huber K, Binder BR. Plasma levels of uPA and scuPA in patients suffering from coronary artery disease. Fibrinolysis 1994;8:139 (abstract 392).
33. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995;74:429-436.
34. van Leeuwen RT. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis 1996;10:59-74.
35. Berg KA. A new serum type system in man - The Lp system. Acta Pathol Microbiol Scand 1963;59:369-382.
36. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981;38:51-61.
37. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62: 249-257.
38. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM, Jr. Association of levels of lipoproteins Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74: 758-765.
39. Eaton DL, Fless GM, Kohr WJ, et al. Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987;84:3224-3228.
40. McConathy WJ, Trieu VN. Lp(a) interactions. Prog Lipid Res 1991;30:195-203.
41. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-305.
42. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989;339:301-303.
43. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86:3847-3851.
44. Hearn JA, Donohue BC, Ba'albaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-739.
45. Tenda K, Saikawa T, Maeda T, et al. The relationship between serum lipoprotein (a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J 1993;57:789-795.
46. Desmarais RL, Saremboek IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-1409.
47. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: Role of lipoprotein (a). Am Heart J 1995;130:1168-1173.
48. Miyata M, Biro S, Armina S, et al. High serum concentration of lipoprotein (a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996;132: 269-273.
49. Kotamäki M, Laustiola K, Syvänne M, Heikkilä J. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty. J Intern Med 1996;240:293-301.
50. van Bockxmeer FM, Mamotte CD, Gibbsons FR, Taylor RR. Apolipoprotein epsilon 4 homozygosity - a determinant of restenosis after coronary angioplasty. Atherosclerosis 1994; 110:195-202.
51. Cooke T, Sheahan R, Foley D, et al. Lipoprotein (a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994;89: 1593-1598.
52. Ishikawa Y, Fujioka Y, Kitagawa Y, et al. Restenosis after percutaneous transluminal coronary angioplasty in the elderly - risk factor analysis. Nippon Ronen Igakkai Zasshi 1995;32:491-496.
53. Bussiere JL, Bourayne J, Monsegu J, et al. Is plasma lipoprotein (a) level a reliable indicator predicting restenosis after angioplasty? Arch Mal Coeur Vaiss 1996;89:425-429.
54. Kanemitsu S, Tekekoshi N, Murakami E. Effects of LDL apheresis on restenosis after angioplasty. Chem Phys Lipids 1994;67-68:339-343.
55. Daida H, Lee YJ, Yokoi H, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994; 73:1037-1040.
56. Liu AC, Lawn RM. Vascular interactions of lipoprotein (a). Curr Opin Lipidol 1994;5:269-273.
57. Hamsten A, Wiman B, de Faire U, Blombaeck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
58. Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator in the blood of patients with coronary artery disease. Br Med J Clin Res Ed 1985;291:573-574.
59. Hamsten A, Blombaeck M, Wiman B, et al. Haemostatic function in myocardial infarction. Br Heart J 1986;55:58-66.
60. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
61. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989;113:88-93.
62. Huber K, Resch I, Stefenelli T, et al. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 1990;63:336-339.
63. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992;95:105-117.
64. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: Platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997;133:387-392.
65. Ishiwata S, Nakanishi S, Nishiyama S, Seki A. Prevention of restenosis by bezafibrate after successful coronary angioplasty. Cor Art Dis 1995;6:883-889.
66. Huber K, Binder BR. Plasminogen activator inhibitor-1 plasma levels and coronary restenosis. Circulation 1992;86: 1661-1662.
67. Lins M, Zuborn KH, Dau O, et al. Coagulation activation in patients undergoing directional coronary atherectomy. Thromb Res 1997;86:433-441.
68. Sehneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002.
69. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 expression in vivo. Thromb Haemost 1993;70:135-137.
70. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13:1090-1100.
71. Wojta J, Gallicchio M, Zoellner H, et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 1993;70:469-474.
72. Noda-Heiny H, Pujii S, Sobel BE. Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. Circ Res 1993;72:36-43.
73. Reilly CP, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991;266:9419-9427.
74. Sawa H, Lundgren C, Sobel BE, Pujii S. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis. J Am Coll Cardiol 1994;24:1742-1748.
75. Christ G, Hufnagl P, Kaun C, et al. Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo. Arterioscler Thromb Vasc Biol 1997;17:723-730.
76. Christ G, Seiffert D, Hufnagl P, et al. Type 1 plasminogen activator inhibitor synthesis of endothelial cells is down-regulated by smooth muscle cells. Blood 1993;81:1277-1283.
77. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation 1997;96:3180-3191.
78. Loskutoff DJ. PAI-1 inhibits neointimal formation after arterial injury in mice. Circulation 1997;96:2772-2774.
79. 3 binding to vitronectin. Nature 1996;383:441-443.
80. He CS, Wilhelm SM, Pentlanf AP, Manner BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-2636.
81. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGPs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13:481-486.
82. Tkachuk V, Stepanova V, Little PJ, Bobik A. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin Exp Pharmacol Physiol 1996;23:759-765.
83. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system. J Cell Biol 1990;111:757-763.
84. Rifkin DB, Moscatelli D, Bizik J, et al. Growth factor control of extracellular proteolysis. Cell Differ Dev 1990;32:313-318.
85. Lauffenburger DA. Making connections count. Nature 1996;383:390-391.
86. Kirchheimer JC, Wojta J, Christ G, Binder BR. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987;1:125-128.
87. Kirchheimer JC, Wojta J, Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 1989;86:5424-5428.
88. Rabbani SA, Mazar AP, Bernier SM, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992;267:14151-14156.
89. He CJ, Rebibou JM, Peraldi MN, Meulders Q, Rondeau E. Growth factor-like effect of urokinase type plasminogen activator in human renais cells. Biochem Biophys Res Commun 1991;176:1408-1416.
90. Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996;271:8215-8220.
91. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells: A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993;91:1541-1552.
92. Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN- inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol 1996; 157:2610-2617.
93. Kirchheimer JC, Binder BR, Remold HG. Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of monocytes into interstitial tissue. J Immunol 1990;145: 1518-1522.
94. Lundgren CH, Sawa H, Sobel BE, Pujii S. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy. Circulation 1994;90:1927-1934.
95. Gottsauner-Wolf M, Sochor H, Hornykewycz S, et al. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients. Thromb Haemost 1999; April, in press.